Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?
Eye (Lond)
.
2023 Jul;37(10):1953-1954.
doi: 10.1038/s41433-022-02287-w.
Epub 2022 Oct 17.
Authors
Ashish Sharma
1
,
Nilesh Kumar
2
,
Nikulaa Parachuri
3
,
Carl Regillo
4
,
Francesco Bandello
5
,
Baruch D Kuppermann
6
Affiliations
1
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India. drashish79@hotmail.com.
2
Madhavi Netralaya, Ara, Bihar, India.
3
Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, TN, India.
4
The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, PA, USA.
5
University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
6
Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.
PMID:
36253457
PMCID:
PMC10333342
DOI:
10.1038/s41433-022-02287-w
No abstract available
MeSH terms
Angiogenesis Inhibitors / therapeutic use
Biosimilar Pharmaceuticals*
Humans
Physicians*
Ranibizumab / therapeutic use
Retina
Substances
Ranibizumab
Biosimilar Pharmaceuticals
Angiogenesis Inhibitors